LEADER trial: difference between revisions
Diff·revision 10 → 11·14:19, 24 Jan 2025
Difference between revision 10 and revision 11 of LEADER trial. 6 lines changed; the page grew by 99 bytes.
| Revision 10 — 02:08, 8 Jan 2025 ReportReaderRilla (talk) add the discontinuation rate for adverse events in both arms 3,178 bytes +45 | Revision 11 — 14:19, 24 Jan 2025 StubSorterBot (talk) bot: sort category members 3,277 bytes +99 | ||
|---|---|---|---|
| 37 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 37 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| 38 | 38 | ||
| + | 39 | == See also == | |
| + | 40 | * [[Liraglutide]] | |
| + | 41 | * [[SELECT trial]] | |
| + | 42 | * [[FLOW trial]] | |
| + | 43 | * [[GLP-1 receptor agonist]] | |
| + | 44 | ||
| 39 | {{DEFAULTSORT:LEADER trial}} | 45 | {{DEFAULTSORT:LEADER trial}} |
| 40 | [[Category:Cardiovascular outcome trials]] | 46 | [[Category:Cardiovascular outcome trials]] |